Luciani L, LOllivier C, Million M, Amphoux B, Edouard S, Raoult D
J Clin Microbiol. 2019; 57(10).
PMID: 31366688
PMC: 6760940.
DOI: 10.1128/JCM.00539-19.
Dvorak C, Akkutay-Yoldar Z, Stone S, Tousignant S, Vannucci F, Murtaugh M
BMC Vet Res. 2017; 13(1):50.
PMID: 28202026
PMC: 5312445.
DOI: 10.1186/s12917-017-0967-x.
Qiu J, Soderlund-Venermo M, Young N
Clin Microbiol Rev. 2016; 30(1):43-113.
PMID: 27806994
PMC: 5217800.
DOI: 10.1128/CMR.00040-16.
Prince H, Lape-Nixon M
Clin Vaccine Immunol. 2014; 21(10):1377-84.
PMID: 25165026
PMC: 4266349.
DOI: 10.1128/CVI.00487-14.
De Paschale M, Clerici P
World J Virol. 2013; 1(1):31-43.
PMID: 24175209
PMC: 3782265.
DOI: 10.5501/wjv.v1.i1.31.
Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection.
Gaudy-Graffin C, Lesage G, Kousignian I, Laperche S, Girault A, Dubois F
J Clin Microbiol. 2010; 48(9):3281-7.
PMID: 20610669
PMC: 2937703.
DOI: 10.1128/JCM.00303-10.
Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.
Wang P, Yang X
J Virol. 2010; 84(14):7114-23.
PMID: 20463081
PMC: 2898255.
DOI: 10.1128/JVI.00545-10.
Development of fully automated determination of marker-specific immunoglobulin G (IgG) avidity based on the avidity competition assay format: application for Abbott Architect cytomegalovirus and Toxo IgG Avidity assays.
Curdt I, Praast G, Sickinger E, Schultess J, Herold I, Braun H
J Clin Microbiol. 2009; 47(3):603-13.
PMID: 19129411
PMC: 2650902.
DOI: 10.1128/JCM.01076-08.
ABO, D blood typing and subtyping using plug-based microfluidics.
Kline T, Runyon M, Pothiawala M, Ismagilov R
Anal Chem. 2008; 80(16):6190-7.
PMID: 18646778
PMC: 2592685.
DOI: 10.1021/ac800485q.
Evaluation of commercial rubella immunoglobulin G avidity assays.
Mubareka S, Richards H, Gray M, Tipples G
J Clin Microbiol. 2006; 45(1):231-3.
PMID: 17093027
PMC: 1828953.
DOI: 10.1128/JCM.01243-06.
Use of immunoglobulin g avidity to determine the course of disease in visceral and post-kala-azar dermal leishmaniasis patients.
Redhu N, Dey A, Balooni V, Singh S
Clin Vaccine Immunol. 2006; 13(8):969-71.
PMID: 16894000
PMC: 1539110.
DOI: 10.1128/CVI.00149-06.
Humoral immune response to primary rubella virus infection.
Wilson K, Di Camillo C, Doughty L, Dax E
Clin Vaccine Immunol. 2006; 13(3):380-6.
PMID: 16522781
PMC: 1391971.
DOI: 10.1128/CVI.13.3.380-386.2006.
Immunoglobulin G avidity in differentiation between early and late antibody responses to West Nile virus.
Fox J, Hazell S, Tobler L, Busch M
Clin Vaccine Immunol. 2006; 13(1):33-6.
PMID: 16425997
PMC: 1356611.
DOI: 10.1128/CVI.13.1.33-36.2006.
Antibody avidity maturation during severe acute respiratory syndrome-associated coronavirus infection.
Chan P, Lim P, Liu E, Cheung J, Leung D, Sung J
J Infect Dis. 2005; 192(1):166-9.
PMID: 15942907
PMC: 7109913.
DOI: 10.1086/430615.
A new method for determination of varicella-zoster virus immunoglobulin G avidity in serum and cerebrospinal fluid.
Kneitz R, Schubert J, Tollmann F, Zens W, Hedman K, Weissbrich B
BMC Infect Dis. 2004; 4:33.
PMID: 15355548
PMC: 522815.
DOI: 10.1186/1471-2334-4-33.
Seroepidemiology of group C rotavirus infection in England and Wales.
Iturriza-Gomara M, Clarke I, Desselberger U, Brown D, Thomas D, Gray J
Eur J Epidemiol. 2004; 19(6):589-95.
PMID: 15330133
DOI: 10.1023/b:ejep.0000032381.36658.cb.
Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections.
de Souza V, Fernandes S, Araujo E, Tateno A, Oliveira O, Oliveira R
J Clin Microbiol. 2004; 42(4):1782-4.
PMID: 15071049
PMC: 387572.
DOI: 10.1128/JCM.42.4.1782-1784.2004.
Use of immunoglobulin G antibody avidity for differentiation of primary human herpesvirus 6 and 7 infections.
Ward K, Turner D, Parada X, Thiruchelvam A
J Clin Microbiol. 2001; 39(3):959-63.
PMID: 11230411
PMC: 87857.
DOI: 10.1128/JCM.39.3.959-963.2001.
Immunoglobulin G avidity in diagnosis of toxoplasmic lymphadenopathy and ocular toxoplasmosis.
Paul M
Clin Diagn Lab Immunol. 1999; 6(4):514-8.
PMID: 10391853
PMC: 95718.
DOI: 10.1128/CDLI.6.4.514-518.1999.
Increases in the levels of Coxiella burnetii-specific immunoglobulin G1 and G3 antibodies in acute Q fever and chronic Q fever.
Capo C, Iorgulescu I, Mutillod M, Mege J, Raoult D
Clin Diagn Lab Immunol. 1998; 5(6):814-6.
PMID: 9801340
PMC: 96207.
DOI: 10.1128/CDLI.5.6.814-816.1998.